The Indiana Biosciences Research Institute in Indianapolis has announced a partnership with a global information technology consulting company. Massachusetts-based Virtusa Corp. (Nasdaq: VRTU) says the collaboration will involve analyzing synthetic medical data, which isn’t subject to the same privacy regulations as real-world data sets, to accelerate research on diseases like diabetes.
The collaborative analyses, IBRI and Virtusa say, will use Virtusa’s vLife open innovation platform and measure whether synthetic data could be an alternative to real-world datasets.
IBRI Applied Data Sciences Center Director Daniel Robertson says "partnering with Virtusa will help the IBRI to achieve its objective of enabling regional, large life sciences companies to access data and technologies from a variety of organizations. Through the vLife open innovation platform, we’re exploring enabling Life Sciences firms to accelerate progress towards finding next-level treatments by providing seamless access to focused, timeline-driven collaboration with universities, government entities, healthcare providers, and other research institutes and organizations."
Virtusa acquired Indianapolis-based Apparatus in 2015 in a $34 million deal. The company provides IT infrastructure management services. In September, Virtusa opened its Innovation Center in Indianapolis to serve as an incubation hub to showcase its tech platforms, along with those of its clients and partners.
You can connect to more about the partnership by clicking here.